Singulex's proprietary ultrasensitive research test for cardiac troponin-I predicts coronary heart disease in the general population
Singulex, Inc., the developer and leading provider of Single Molecule Counting (SMC(tm)) technology for clinical diagnostics and scientific discovery, yesterday presented new data at the American Heart Association Epidemiology and Prevention Council Conference highlighting research results using the Company's proprietary ultrasensitive Erenna® Immunoassay System in the detection of cardiac troponin-I (cTnI). The study utilized the Erenna System to measure previously undetected increases in cTnI to predict development of coronary heart disease (CHD) in the general population, independent of a variety of traditional risk factors.
"In this large prospective study utilizing Singulex's uniquely sensitive technology, we were able to measure troponin-I in virtually every patient in the cohort," said Dr. Wolfgang Koenig, MD, PhD, FRCP, FESC, FACC, FAHA, Professor of Medicine/Cardiology at the Department of Internal Medicine - II Cardiology at the University of Ulm Medical School, Ulm, Germany. "The results demonstrate that Singulex's research troponin-I test can predict incident coronary heart disease in the general population which, I believe, ultimately brings greater insight into the cardiovascular risk profile of individuals who have not already been diagnosed with the disease."
The study, led by Dr. Koenig, focused on the association between increased concentrations of cardiac troponin-I and increased risk of CHD. The population-based study was the first with significant long-term follow-up to demonstrate that modestly increased concentrations of cardiac troponin-I are linked to future CHD events.
"Coronary heart disease is the leading cause of death in the United States for men and women and costs our healthcare system over $100 billion each year," said Guido Baechler, President and Chief Executive Officer of Singulex. "The insightful work of collaborators, like Dr. Koenig, highlights the importance of utilizing ultrasensitive SMC technology to measure troponin-I. These precise measurements can help physicians monitor disease progression and better manage their patients with chronic disease."
The study was conducted in middle-aged healthy men and women without known heart disease at the time of study entry within the MONICA/KORA Augsburg studies. Serum levels of cardiac troponin-I were available in 2,745 men and women, and included 803 new cases of CHD. The average baseline concentration, or level, of cardiac troponin-I across all of the 2,745 subjects was 1.56 ng/L (1.56 pg/mL). Baseline concentrations of cardiac troponin-I were higher in CHD cases compared to non-cases (mean 2.56 vs. 1.49 ng/L, p<0.0001). After adjustment for variables of the Framingham Risk Score, the hazard ratio (HR) with 95% confidence interval (CI) for a CHD event in the top quartile (subjects with the highest cardiac troponin-I levels) compared to the bottom quartile (subjects with the lowest cardiac troponin-I values) was 2.76 (95% CI, 1.87-4.09). Thus, there was a 2.76 fold increase in risk for developing coronary heart disease in the patients with high baseline cardiac troponin-I levels compared to patients with low baseline levels. After additional adjustment for alcohol intake, physical activity and body mass index, relative risk remained essentially unchanged. Singulex's SMC technology measured cTnI at the picogram/mL level and predicted which patients would develop CHD.
The poster, Ultrasensitive troponin-I strongly predicts incident coronary heart disease in the general population independently of traditional risk factors. Results from the MONICA/KORA Augsburg Case-Cohort Study, by Wolfgang Koenig, MD, et al, was presented at the 2014 American Heart Association Epidemiology and Prevention Scientific Sessions that are being held at the Hilton San Francisco Union Square in San Francisco.